Search by Drug Name or NDC

    NDC 52654-0001-01 MP 32; 32; 32; 32; 32; 32; 32 [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL Details

    MP 32; 32; 32; 32; 32; 32; 32 [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL

    MP is a ORAL LIQUID in the HUMAN OTC DRUG category. It is labeled and distributed by Chi Research, Inc.. The primary component is ACHYROCLINE SATUREIOIDES; ARCTOSTAPHYLOS UVA-URSI LEAF; MIRABILIS JALAPA FLOWERING TOP; PETIVERIA ALLIACEA WHOLE; PHYSALIS ANGULATA; SCHINUS MOLLE BARK; SENNA OCCIDENTALIS.

    Product Information

    NDC 52654-0001
    Product ID 52654-0001_4a7d8678-91fc-4a07-84b8-e613d23ac512
    Associated GPIs
    GCN Sequence Number n/a
    GCN Sequence Number Description n/a
    HIC3 n/a
    HIC3 Description n/a
    GCN n/a
    HICL Sequence Number n/a
    HICL Sequence Number Description n/a
    Brand/Generic n/a
    Proprietary Name MP
    Proprietary Name Suffix n/a
    Non-Proprietary Name Achyrocline Satureioides, Arctostaphylos Uva Ursi Leaf, Cassia Occidentalis, Mirabilis Jalapa, Petiveria Alliacea, Physalis Angulata, Schinus Molle
    Product Type HUMAN OTC DRUG
    Dosage Form LIQUID
    Route ORAL
    Active Ingredient Strength 32; 32; 32; 32; 32; 32; 32
    Active Ingredient Units [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL
    Substance Name ACHYROCLINE SATUREIOIDES; ARCTOSTAPHYLOS UVA-URSI LEAF; MIRABILIS JALAPA FLOWERING TOP; PETIVERIA ALLIACEA WHOLE; PHYSALIS ANGULATA; SCHINUS MOLLE BARK; SENNA OCCIDENTALIS
    Labeler Name Chi Research, Inc.
    Pharmaceutical Class n/a
    DEA Schedule n/a
    Marketing Category UNAPPROVED HOMEOPATHIC
    Application Number n/a
    Listing Certified Through n/a

    Package

    NDC 52654-0001-01 (52654000101)

    NDC Package Code 52654-0001-1
    Billing NDC 52654000101
    Package 120 mL in 1 BOTTLE, DROPPER (52654-0001-1)
    Marketing Start Date 2016-05-18
    NDC Exclude Flag N
    Pricing Information N/A

    Standard Product Labeling (SPL)/Prescribing Information SPL 6e88db05-aeb3-4a97-857c-da4dbc3ad39f Details

    Revised: 11/2022